MGT Capital Investments, Inc.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joshua Silverman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Joshua Silverman has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TAOX / TAO Synergies Inc. Executive Chairman, Director 26,681
US:PTPI / Petros Pharmaceuticals, Inc. Director 1,011,237
US:AYRO / StableX Technologies, Inc. Executive Chairman, Director 189,323
US:PMCB / PharmaCyte Biotech, Inc. Director 50,000
US:MYMD / MyMD Pharmaceuticals, Inc. Director 88,775
Director 0
US:PTIX / Protagenic Therapeutics, Inc. Director 120,000
US:TPIV / TapImmune, Inc. Director 17,221
Director 414,323
US:ALAN / Alanco Technologies Inc Director 948,796
US:MGT / MGT Capital Investments, Inc. Director 600,000
US:TWFH / 24Holdings, Inc. 10% Owner 693,558
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joshua Silverman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases MGTI / MGT Capital Investments, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2015-10-08 MGT Silverman Joshua 300,000 300,000 731

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MGTI / MGT Capital Investments, Inc. Insider Trades
Insider Sales MGTI / MGT Capital Investments, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MGTI / MGT Capital Investments, Inc. Insider Trades
Insider Purchases MRKR / Marker Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRKR / Marker Therapeutics, Inc. Insider Trades
Insider Sales MRKR / Marker Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRKR / Marker Therapeutics, Inc. Insider Trades
Insider Purchases PMCB / PharmaCyte Biotech, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PMCB / PharmaCyte Biotech, Inc. Insider Trades
Insider Sales PMCB / PharmaCyte Biotech, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PMCB / PharmaCyte Biotech, Inc. Insider Trades
Insider Purchases PTIX / Protagenic Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTIX / Protagenic Therapeutics, Inc. Insider Trades
Insider Sales PTIX / Protagenic Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTIX / Protagenic Therapeutics, Inc. Insider Trades
Insider Purchases PTPI / Petros Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTPI / Petros Pharmaceuticals, Inc. Insider Trades
Insider Sales PTPI / Petros Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTPI / Petros Pharmaceuticals, Inc. Insider Trades
Insider Purchases SBLX / StableX Technologies, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-06-26 DCAR Silverman Joshua 5,000 1.2875 5,000 1.2875 6,438 273
2018-06-25 DCAR Silverman Joshua 11,700 1.2456 11,700 1.2456 14,574
2018-06-22 DCAR Silverman Joshua 13,300 1.2702 13,300 1.2702 16,894

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SBLX / StableX Technologies, Inc. Insider Trades
Insider Sales SBLX / StableX Technologies, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-08-01 AYRO Silverman Joshua 12,740 0.8152 1,062 9.7824 10,386 45 0.4854 -9,870 -95.04
2023-05-03 AYRO Silverman Joshua 11,927 0.4874 994 5.8488 5,813
2023-01-30 AYRO Silverman Joshua 7,171 0.7123 598 8.5476 5,108
2022-11-01 AYRO Silverman Joshua 7,171 0.5919 598 7.1028 4,245
2022-05-11 AYRO Silverman Joshua 12,855 0.8200 1,071 9.8400 10,541
2021-06-04 AYRO Silverman Joshua 39,008 5.1704 3,251 62.0448 201,687

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SBLX / StableX Technologies, Inc. Insider Trades
Insider Purchases TAOX / TAO Synergies Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-06-14 SNPX Silverman Joshua 10,000 8.3000 400 207.5000 83,000 232 252.25 17,900 21.57

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TAOX / TAO Synergies Inc. Insider Trades
Insider Sales TAOX / TAO Synergies Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TAOX / TAO Synergies Inc. Insider Trades
Insider Purchases TNFA / TNF Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGTI / MGT Capital Investments, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-11-26 MYMD Silverman Joshua 5,000 7.5543 167 226.6290 37,772 4 7.66 -36,499 -96.63
2021-11-24 MYMD Silverman Joshua 6,734 6.2991 224 188.9730 42,418
2021-11-24 MYMD Silverman Joshua 3,266 7.0937 109 212.8110 23,168

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TNFA / TNF Pharmaceuticals, Inc. Insider Trades
Insider Sales TNFA / TNF Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGTI / MGT Capital Investments, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TNFA / TNF Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Joshua Silverman as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-02 2025-06-30 4 TAOX TAO Synergies Inc.
Common Stock, par value $0.0001 per share
F - Taxes -16,768 26,681 -38.59 7.85 -131,629 209,446
2025-07-02 2025-06-30 4 TAOX TAO Synergies Inc.
Common Stock, par value $0.0001 per share
A - Award 41,919 43,449 2,739.80
2025-02-21 2025-02-19 4 PTPI Petros Pharmaceuticals, Inc.
Common Stock
A - Award 1,000,000 1,011,237 8,899.17
2024-12-02 2024-12-02 4 AYRO AYRO, Inc.
Common Stock
A - Award 146,052 189,323 337.53
2024-12-02 2024-12-02 4 AYRO AYRO, Inc.
Common Stock
D - Sale to Issuer -6,166 43,271 -12.47
2023-08-03 2023-08-01 4 AYRO AYRO, Inc.
Common Stock
S - Sale -12,740 395,493 -3.12 0.82 -10,386 322,406
2023-05-05 2023-05-03 4 AYRO AYRO, Inc.
Common Stock
S - Sale -11,927 408,233 -2.84 0.49 -5,813 198,973
2023-04-28 2023-04-26 4 PTPI Petros Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,722 11,237 148.88
2023-02-03 2023-02-01 4 AYRO AYRO, Inc.
Common Stock
A - Award 197,333 420,160 88.56
2023-02-03 2023-01-30 4 AYRO AYRO, Inc.
Common Stock
S - Sale -7,171 222,827 -3.12 0.71 -5,108 158,720
2023-01-25 2023-01-20 4 PTPI Petros Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,515 4,515 125.75
2022-12-20 2022-12-16 4 SNPX Synaptogenix, Inc.
Common Stock, par value $0.0001 per share
S - Sale X -19,012 38,238 -33.21 1.17 -22,280 44,811
2022-12-01 2021-07-13 4/A SNPX Synaptogenix, Inc.
Common Stock, par value $0.0001 per share
A - Award 42,250 57,250 281.67
2022-11-03 2022-11-01 4 AYRO AYRO, Inc.
Common Stock
S - Sale -7,171 229,998 -3.02 0.59 -4,245 136,136
2022-11-03 2022-05-11 4 AYRO AYRO, Inc.
Common Stock
S - Sale -12,855 237,169 -5.14 0.82 -10,541 194,479
2022-08-23 3 PMCB PharmaCyte Biotech, Inc.
Common Stock
50,000
2022-04-11 2022-04-07 4 PTPI Petros Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 67,227 67,227
2022-04-06 2022-04-05 4 SNPX Synaptogenix, Inc.
Stock Option (Right to Buy)
A - Award 1,500 1,500
2022-02-03 2022-02-01 4 AYRO AYRO, Inc.
Common Stock
A - Award 114,729 250,024 84.80
2022-01-07 2021-12-22 4 PTPI Petros Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 25,156 25,156
2021-11-29 2021-11-26 4 MYMD MyMD Pharmaceuticals, Inc.
Common Stock
P - Purchase 5,000 88,775 5.97 7.55 37,772 670,633
2021-11-29 2021-11-24 4 MYMD MyMD Pharmaceuticals, Inc.
Common Stock
P - Purchase 3,266 83,775 4.06 7.09 23,168 594,275
2021-11-29 2021-11-24 4 MYMD MyMD Pharmaceuticals, Inc.
Common Stock
P - Purchase 6,734 80,509 9.13 6.30 42,418 507,134
2021-10-15 2021-10-14 4 MYMD MyMD Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 600,000 600,000
2021-07-15 2021-07-13 4 SNPX Synaptogenix, Inc.
Common Stock, par value $0.0001 per share
A - Award 90,000 105,000 600.00
2021-06-16 2021-06-14 4 SNPX Synaptogenix, Inc.
Common Stock, par value $0.0001 per share
P - Purchase 10,000 15,000 200.00 8.30 83,000 124,500
2021-06-14 3 SNPX Synaptogenix, Inc.
Common Stock, par value $0.0001 per share
5,000
2021-06-08 2021-06-04 4 AYRO AYRO, Inc.
Common Stock
S - Sale -39,008 135,295 -22.38 5.17 -201,687 699,529
2021-04-20 2021-04-16 4 MYMD MyMD Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -109,500 0 -100.00
2021-04-20 2021-04-16 4 MYMD MyMD Pharmaceuticals, Inc.
Common Stock
F - Taxes -38,325 71,175 -35.00 4.94 -189,326 351,604
2021-04-20 2021-04-16 4 MYMD MyMD Pharmaceuticals, Inc.
Common Stock
M - Exercise 109,500 112,101 4,209.92
2021-04-09 2021-04-08 4 PTPI Petros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2021-02-26 2021-02-24 4 AYRO AYRO, Inc.
Common Stock
A - Award 42,000 174,303 31.75
2020-12-28 2020-09-29 4/A AYRO AYRO, Inc.
Common Stock
A - Award 122,547 132,303 1,256.12
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -100,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -10,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -10,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -10,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -150,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -10,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -167,000 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -124,275 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
D - Sale to Issuer -9,375 0 -100.00
2020-12-03 2020-12-01 4 NTRP Neurotrope, Inc.
Common Stock
D - Sale to Issuer -100,000 0 -100.00
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 20,000 20,000
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 2,000 2,000
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 2,000 2,000
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 2,000 2,000
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 30,000 30,000
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 2,000 2,000
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 33,400 33,400
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 24,855 24,855
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 1,875 1,875
2020-12-02 2020-12-01 4 PTPI Petros Pharmaceuticals, Inc.
Common Stock, par value $0.0001 per share
A - Award 20,000 20,000
2020-11-27 2020-11-24 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 100,000 100,000
2020-10-20 2020-10-16 4 NTRP Neurotrope, Inc.
Common Stock
P - Purchase 50,000 100,000 100.00 1.09 54,445 108,890
2020-10-19 2020-10-15 4 NTRP Neurotrope, Inc.
Common Stock
P - Purchase 50,000 50,000 1.07 53,315 53,315
2020-10-01 2020-09-29 4 AYRO AYRO, Inc.
Common Stock
A - Award 122,547 132,303 1,256.12
2020-09-11 2020-09-11 4 AKER Akers Biosciences, Inc.
Restricted Stock Unit
A - Award 219,000 219,000
2020-06-01 2020-05-28 4 AYRO AYRO, Inc.
Common Stock
A - Award 9,756 9,756
2020-03-24 2020-03-20 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2020-02-26 2020-02-21 4 PTIX Protagenic Therapeutics, Inc.\new
PTIX Common stock Options
A - Award 120,000 120,000
2020-01-03 2020-01-01 4 AKER Akers Biosciences, Inc.
Restricted Stock Units
M - Exercise 5,201 0 -100.00
2020-01-03 2020-01-01 4 AKER Akers Biosciences, Inc.
Common Stock
M - Exercise 5,201 5,201
2019-08-29 2019-08-27 4 DCAR DropCar, Inc.
Common Stock
F - Taxes -14,972 69,915 -17.64 0.78 -11,678 54,534
2019-08-29 2019-08-27 4 DCAR DropCar, Inc.
Common Stock
A - Award 75,950 84,887 849.84
2019-04-15 2019-03-15 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2019-04-02 2019-03-29 4 AKER Akers Biosciences, Inc.
Restricted Stock Units
A - Award 124,827 124,827
2019-02-22 2019-02-11 4 DCAR DropCar, Inc.
Warrant to purchase Common Stock
J - Other 1,161 1,161
2019-02-22 2019-02-11 4 DCAR DropCar, Inc.
Warrant to purchase Common Stock
J - Other 1,716 1,716
2019-02-22 2019-02-11 4 DCAR DropCar, Inc.
Warrant to purchase Common Stock
J - Other 2,223 2,223
2019-02-22 2019-02-11 4 DCAR DropCar, Inc.
Warrant to purchase Common Stock
J - Other 1,667 1,667
2019-01-24 2019-01-22 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 150,000 150,000
2018-12-03 2018-05-14 4 DCAR DropCar, Inc.
Stock option (right to buy)
A - Award 18,282 18,282
2018-10-17 2018-10-16 4 TPIV TAPIMMUNE INC.
Common Stock
A - Award 4,106 17,221 31.31
2018-06-26 2018-06-26 4 DCAR DropCar, Inc.
Common Stock
P - Purchase 5,000 35,109 16.61 1.29 6,438 45,203
2018-06-26 2018-06-25 4 DCAR DropCar, Inc.
Common Stock
P - Purchase 11,700 30,109 63.56 1.25 14,574 37,504
2018-06-26 2018-06-22 4 DCAR DropCar, Inc.
Common Stock
P - Purchase 13,300 18,409 260.32 1.27 16,894 23,383
2018-03-15 2018-03-13 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Series F Warrants
J - Other 49,167 49,167
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Series E-1 Warrants
J - Other 31,093 31,093
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Series E Warrants
J - Other 10,574 10,574
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Series A Warrants
J - Other 41,667 41,667
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Series D Warrants
J - Other 41,667 41,667
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Series C Warrants
J - Other 44,000 44,000
2018-03-02 2018-02-28 4 TPIV TAPIMMUNE INC.
Common Stock
J - Other 153,333 153,333
2018-03-02 2018-02-28 4 DCAR DropCar, Inc.
Warrants
J - Other 1,716 1,716
2018-03-02 2018-02-28 4 DCAR DropCar, Inc.
Warrants
J - Other 2,222 2,222
2018-03-02 2018-02-28 4 DCAR DropCar, Inc.
Warrants
J - Other 1,161 1,161
2018-03-02 2018-02-28 4 DCAR DropCar, Inc.
Warrants
J - Other 1,667 1,667
2018-03-02 2018-02-28 4 DCAR DropCar, Inc.
Common Stock
J - Other 5,109 5,109
2017-10-18 2017-10-16 4 PTIX Protagenic Therapeutics, Inc.\new
Non-Qualified Stock Options (Right to Buy)
A - Award 45,000 45,000
2017-08-30 2017-08-29 4 TPIV TAPIMMUNE INC.
Common Stock
A - Award 13,115 13,115
2017-05-02 2017-04-28 4 WPCS WPCS INTERNATIONAL INC
Stock Option (right to purchase)
A - Award 50,000 50,000
2017-04-13 2017-04-11 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 167,000 167,000
2017-03-21 2017-03-17 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2016-11-30 2016-11-28 4 TPIV TAPIMMUNE INC
Employee Stock Option (Right to Buy)
A - Award 12,500 12,500
2016-11-23 2016-11-21 4 NTRP Neurotrope, Inc.
Stock Option
A - Award 3,976,767 3,976,767
2016-09-13 2016-09-12 4 NHLD NATIONAL HOLDINGS CORP
Common Stock, par value $0.02 per share
U - Other 414,323 414,323 3.25 1,346,550 1,346,550
2016-08-25 3 WPCS WPCS INTERNATIONAL INC
Common Stock
528,536
2016-08-25 3 WPCS WPCS INTERNATIONAL INC
Common Stock
277,279
2016-08-25 3 WPCS WPCS INTERNATIONAL INC
Common Stock
528,536
2016-08-25 3 WPCS WPCS INTERNATIONAL INC
Common Stock
277,279
2016-08-19 2016-08-04 4/A NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2016-08-19 2016-08-04 4/A NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 250,000 250,000
2016-08-08 2016-08-04 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2016-08-08 2016-08-04 4 NTRP Neurotrope, Inc.
Stock Option (right to buy)
A - Award 250,000 250,000
2016-08-08 3 NTRP Neurotrope, Inc.
Common Stock
450,000
2016-08-08 3 NTRP Neurotrope, Inc.
Common Stock
450,000
2016-06-21 2016-06-17 4 ATRN Protagenic Therapeutics, Inc.\new
NSO
A - Award 45,000 45,000 1.25 56,250 56,250
2016-03-11 3 ALAN ALANCO TECHNOLOGIES INC
Class A Common Stock
948,796
2016-03-11 3 ALAN ALANCO TECHNOLOGIES INC
Class A Common Stock
948,796
2016-02-16 2015-10-08 5 MGT MGT CAPITAL INVESTMENTS INC
Warrant to Purchase Common Stock (Right to Buy}
P - Purchase 600,000 600,000
2016-02-16 2015-10-08 5 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
P - Purchase 300,000 1,339,096 28.87
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
1,087,834
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
2,029,454
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
1,087,834
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
2,029,454
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
1,087,834
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
2,029,454
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
1,087,834
2014-10-09 3 MGT MGT CAPITAL INVESTMENTS INC
Common Stock, $0.001 Par Value
2,029,454
2014-08-07 3 NHLD NATIONAL HOLDINGS CORP
Common Stock, $0.02 Par Value
16,572,910
2014-08-07 3 NHLD NATIONAL HOLDINGS CORP
Common Stock, $0.02 Par Value
16,572,910
2013-05-14 2013-05-09 4 TWFH 24HOLDINGS INC
Common Stock
P - Purchase 344,210 693,558 98.53 0.19 66,983 134,966
2013-05-14 3 TWFH 24HOLDINGS INC
Common Stock
349,348
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)